Brief: Apogee Therapeutics Inc - Enters Master Services Agreement With Samsung Biologics
March 11 (Reuters) - Apogee Therapeutics Inc APGE.O: APOGEE THERAPEUTICS INC - ENTERS MASTER SERVICES AGREEMENT WITH SAMSUNG BIOLOGICS APOGEE THERAPEUTICS INC - SAMSUNG TO MANUFACTURE AND SUPPLY APG777 FOR APOGEE APOGEE THERAPEUTICS INC - MSA TO TERMINATE IN FEBRUARY 2035 Source text: [ID:n0001104659-25-022371] Further company coverage: APGE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apogee Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Abbvie Seeks At Least $8 Billion In Debt To Fund Apogee Deal - Bloomberg News
Street View: Strength in AbbVie's immunology pipeline to support revenue growth
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates (updated)